Cited by 100Mental Health Treatment and AccessHealth Systems, Economic Evaluations, Quality of LifeSchizophrenia research and treatment

Cost effectiveness of strategies to combat neuropsychiatric conditions in sub-Saharan Africa and South East Asia: mathematical modelling study

Open access
Chisholm, D., Saxena, S.·2012·BMJ

Abstract

OBJECTIVE: To assess the comparative costs and effects of interventions to combat five neuropsychiatric conditions (schizophrenia, bipolar disorder, depression, epilepsy, and heavy alcohol use). DESIGN: Cost effectiveness analysis based on an epidemiological model. SETTING: Two epidemiologically defined World Health Organization sub-regions of the world: countries in sub-Saharan Africa with very high adult and high child mortality (AfrE); and countries in South East Asia with high adult and high child mortality (SearD). DATA SOURCES: Published studies, costing databases. MAIN OUTCOME MEASURES: Cost per capita and cost per disability adjusted life year (DALY) averted, expressed in international dollars ($Int) for the year 2005. RESULTS: Across 44 assessed intervention strategies for the five neuropsychiatric conditions, cost effectiveness values differed by as much as two orders of magnitude (from $Int100-250 to $Int10,000-25,000 for a year of healthy life gained). In both sub-regions, inpatient based treatment of schizophrenia with newer antipsychotic drugs was the most costly and least cost effective strategy. The most cost effective strategies in the African sub-region related to population based alcohol control, while in the South East Asian sub-region the most cost effective intervention was drug treatment of epilepsy in primary care. The cumulative cost per capita of the most cost effective set of interventions covering all five conditions was estimated at $Int4.90-5.70. This package comprises interventions for epilepsy (older first line antiepileptic drugs); depression (generically produced newer antidepressants and psychosocial treatment); bipolar disorder (mood stabiliser drug lithium); schizophrenia (neuroleptic antipsychotic drugs and psychosocial treatment); and heavy alcohol use (increased taxation and its enforcement, reduced access, and, in the African sub-region, advertising bans and brief advice to heavy drinkers in primary care). CONCLUSIONS: Reallocation of resources to cost effective intervention strategies would increase health gain, save money and help implement much needed expansion of services for neuropsychiatric conditions in low resource settings.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmj.e609

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • These systems fall short of delivering the health gains theoretically attainable with current technologies.

    “These systems fall short of delivering the health gains theoretically attainable with current technologies. 444,455,456”

    From The Lancet Psychiatry Commission on youth mental health (2024) · cites this paper as [444]

    The Introduction describes a large treatment gap for neuropsychiatric conditions in developing regions, and Key findings and implications says current practice in the two studied sub-regions invests little in more cost-effective interventions. This supports unrealized health gains from available interventions, but the paper does not establish the claim for health systems or health gains generally beyond those conditions and settings. (LLM, conf=0.82)

    Experimental — accuracy not yet measured
  • Economic modelling work for the general population in all WHO regions indicates that investment in both pharmacological and psychological therapies can be cost-effective even in the most resource-constrained regions of the world.

    “Economic modelling work for the general population in all WHO regions indicates that investment in both pharmacological and psychological therapies can be costeffective even in the most resource-constrained regions of the world. 444,445”

    From The Lancet Psychiatry Commission on youth mental health (2024) · cites this paper as [444]

    The Results and What this study adds sections report cost-effective drug treatments and include psychosocial treatment in the assessed intervention package for resource-constrained settings. But the modelling covers two WHO sub-regions—one in sub-Saharan Africa and one in South East Asia—not all WHO regions. Page numbers are unavailable in our copy. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 16

  1. Jacob KS, Sharan P, Mirza I, Garrido-Cumbrera M, Seedat S, Mari JJ, et al. Mental health systems in countries: where are we now? Lancet 2007;370:1061-77.
  2. Nathan PE, Gorman JM. A guide to treatments that work. 2nd ed. Oxford University Press, 2002.
  3. Babor T, Caetano R, Casswell S, Edwards G. Alcohol: no ordinary commodity-a consumer's guide to public policy . Oxford University Press, 2003.
  4. Engel J, Pedley TA. Epilepsy: a comprehensive textbook . Lippincott-Raven, 1997.
  5. Evans DB, Edejer TT, Adam T, Lim SS. Methods to assess the costs and health effects of interventions for improving health in developing countries. BMJ 2005;331:1137-40.
  6. Chisholm D. Cost-effectiveness of first-line anti-epileptic drug treatments in the developing world: a population-level analysis. Epilepsia 2005;46:751-9.
  7. Chisholm D, Sanderson K, Ayuso-Mateos JL, Saxena S. Reducing the burden of depression: a population-level analysis of intervention cost-effectiveness in 14 epidemiologically-defined sub-regions (WHO-CHOICE). Br J Psychiatry 2004;184:393-403.
  8. Chisholm D, Rehm J, van Ommeren M, Monteiro M, on behalf of WHO-CHOICE. Reducing the global burden of heavy alcohol use: a comparative cost-effectiveness analysis. J Stud Alcohol 2004;65:782-93.
  9. Chisholm D, van Ommeren M, Ayuso-Mateos JL, Saxena S. Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder: a global analysis (WHO-CHOICE). Br J Psychiatry 2005;187:559-67.
  10. Chisholm D, Gureje O, Saldivia S, Villalón Calderón M, Wickremasinghe R, Mendis N, et al. Schizophrenia treatment in the developing world: an inter-regional and multi-national cost-effectiveness analysis. Bull World Health Organ 2008;86:542-51.
  11. Ferri C, Chisholm D, van Ommeren M, Prince M. Resource utilisation for neuropsychiatric disorders in developing countries: a multinational Delphi consensus study. Soc Psychiatry Psychiatr Epidemiol 2004;39:218-27.
  12. Chisholm D, Baltussen R, Evans DB, Ginsberg G, Lauer J, Lim S, et al. What are the priorities for prevention and control of non-communicable diseases and injuries in sub-Saharan Africa and South East Asia? BMJ 2012;344:e586.
  13. Saraceno B, van Ommeren M, Batniji R, Cohen A, Gureje O, Mahoney J, et al. Barriers to improvement of mental health services in low-income and middle-income countries. Lancet 2007;370:1164-74.
  14. Gureje O, Chisholm D, Kola L, Lasebikan V, Saxena S. Cost-effectiveness of an essential mental health intervention package in Nigeria. World Psychiatry 2007;6:42-8.
  15. Salomon JA, Carvalho N, Gutiérrez-Delgado C, Casey A, Hogan DR, Lee D, et al. Intervention strategies to reduce the burden of non-communicable diseases in Mexico: cost effectiveness analysis. BMJ 2012;344:e355.
  16. Chisholm D, Lund C, Saxena S. Cost of scaling up mental healthcare in low-and middle-income countries. Br J Psychiatry 2007;191:528-35.

Cited by

Sorted by citations

Authors
Chisholm, D., & Saxena, S.
Affiliations
World Health Organization (CH)
Corresponding author
Chisholm, D.
Venue
BMJ
Publisher
BMJ
Published
2012-03-02
Volume
344
Issue
mar02 1
Pages
e609-e609
ISSN
  • 0007-1447 (ISSN-L)
  • 0959-8138
  • 1468-5833
OpenAlex
W2048729231
Cited by
100
References
4
Citations by year
2026: 1 · 2025: 4 · 2024: 2 · 2023: 6 · 2022: 2 · 2021: 6 · 2020: 8 · 2019: 6 · 2018: 4 · 2017: 10 · 2016: 19 · 2015: 7 · 2014: 10 · 2013: 8 · 2012: 7
FWCI
15.44
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • BMJ (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Topics
  • Social Sciences › Psychology › Social Psychology › Mental Health Treatment and Access
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords
neuropsychiatric disorders, cost-effectiveness, schizophrenia, bipolar disorder, depression, epilepsy, heavy alcohol use, antipsychotic drugs, antiepileptic drugs, antidepressants, mood stabilizers, alcohol taxation, alcohol advertising ban, psychosocial interventions, disability-adjusted life years, resource-limited settings, sub-Saharan Africa, Southeast Asia, resource allocation
MeSH terms
Alcoholism, Asia, Southeastern, Bipolar Disorder, Cost-Benefit Analysis, Depression, Epilepsy, Female, Humans, Male, Models, Theoretical, Schizophrenia, Africa South of the Sahara

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review